Kidney Function and DKA Risk: Unraveling the Mystery in Type 1 Diabetes
Could kidney function alone predict diabetic ketoacidosis (DKA) risk in type 1 diabetes (T1D) patients? A recent study delves into this question, revealing surprising insights. But here's where it gets controversial: the findings challenge conventional beliefs about kidney health and DKA.
In type 2 diabetes, SGLT inhibitors have proven effective in reducing late-stage kidney issues but also increase DKA risk. However, the study's focus on T1D patients tells a different story. Despite the prevalence of chronic kidney disease in T1D, SGLT inhibitors are not commonly approved for this patient group.
The researchers aimed to clarify whether reduced kidney function, measured by estimated glomerular filtration rate (eGFR), increases DKA risk in T1D. They analyzed data from the DCCT/EDIC study, a long-term project spanning 35 years, involving 1441 adults with T1D.
Key Findings:
- During the study, 297 participants experienced DKA events, totaling 488 occurrences.
- Unadjusted analysis showed no significant difference in DKA rates between individuals with eGFR 30-90 mL/min/1.73 m2 and those with eGFR 90-120 mL/min/1.73 m2 (reference range).
- The incidence rate of the first DKA event was slightly higher in those with eGFR < 30 mL/min/1.73 m2 and lower in the 30-59 mL/min/1.73 m2 and 60-90 mL/min/1.73 m2 ranges, compared to the reference group.
- Adjusted analysis revealed no significantly higher hazard ratio for the first DKA in those with eGFR > 120 mL/min/1.73 m2 compared to the reference group.
And this is the part most people miss: the study's limitations included the young age and good health of participants, lack of central adjudication for DKA confirmation, and missing data on potential confounders like socioeconomic status and alcohol intake.
Despite these limitations, the study's large scale and duration provided robust results. The researchers concluded that the lack of increased DKA risk in T1D patients with reduced eGFR supports the design of clinical trials for SGLT inhibitors, aiming to uncover kidney-protective advantages.
A Twist in the Tale:
The study's results contradict the FinnDiane study, which found higher DKA risk in individuals with end-stage kidney disease or eGFR ≤ 60 mL/min/1.73 m2. However, the researchers attributed this discrepancy to their time-updated analysis, which provided a more current assessment of kidney function.
Expert Commentary:
Charles Leonard, PharmD, MSCE, MPH, who was not involved in the study, emphasized the importance of distinguishing causation from correlation. He noted that while the new data showed no clear link between lower eGFR and higher DKA risk, further research is needed to refine our understanding, especially in advanced kidney disease.
Looking Ahead:
The study paves the way for future investigations to assess DKA risk in patients with established chronic kidney disease, identify benefit subgroups, and develop strategies to minimize DKA risk. These findings may even influence regulatory decisions regarding SGLT inhibitor indications.
What are your thoughts on this study's implications? Do you agree that more research is needed to fully understand the relationship between kidney function and DKA risk in T1D? Share your insights in the comments below!
